BeiGene’s BTK inhibitor brings in $308M, drives Q2 earnings with 46% increase from Q1

BeiGene saw huge growth in its BTK in­hibitor Brukin­sa this quar­ter, mark­ing a 139% in­crease from the same time last year and a 46% in­crease from the first quar­ter.

Brukin­sa brought in $308 mil­lion this quar­ter, dri­ving the com­pa­ny’s 82% in­crease in to­tal prod­uct rev­enue — $554 mil­lion — com­pared to this time last year.

The Brukin­sa growth stems from sev­er­al la­bel ex­pan­sions and ap­provals glob­al­ly this year with the launch of the drug for the treat­ment of adult pa­tients with chron­ic lym­pho­cyt­ic leukemia (CLL) in the US, along with ap­provals for ex­pand­ed in­di­ca­tions in Chi­na, Aus­tralia and Cana­da.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters